Printer Friendly

STEPHANIE MARRUS JOINS VERTEX AS DIRECTOR OF CORPORATE COMMUNICATIONS

STEPHANIE MARRUS JOINS VERTEX AS DIRECTOR OF CORPORATE COMMUNICATIONS
 CAMBRIDGE, Mass., Aug. 13 /PRNewswire/ -- Stephanie K. Marrus has joined Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) in the newly created position of director of corporate communications.
 "Stephanie brings significant high-technology corporate communications experience to Vertex," said Richard Aldrich, Vertex's chief business officer. "Her professional marketing experience and investor orientation will be a major asset for us as the company grows and progresses."
 Marrus' experience includes over 20 years in marketing, business development and corporate strategy. She has served as director of business development for Hewlett-Packard and as president of The Brant Company, a management consulting firm. Prior to Vertex, she served as an official of the Weld Administration, in the Executive Office of Administration and Finance and as deputy secretary for economic affairs, where she represented Gov. Weld on the Biotechnology Subcommittee of the Governor's Council for Economic Growth and Technology.
 Marrus received her A.B. from Cornell University, an M.A. from Columbia University and an M.B.A. from the Wharton School of the University of Pennsylvania.
 Vertex is a leader in the use of structure-based rational drug design, a scientific approach to drug discovery which uses atomic level information to design synthetic compounds that interact with protein targets involved in disease processes. Vertex is using advanced techniques of biology, chemistry and biophysics to create novel, small- molecule compounds that the company plans to develop as orally deliverable drugs to treat major human diseases. Vertex is concentrating on the development of drugs in the areas of immunology, inflammation and antiviral therapy.
 -0- 8/13/92
 /CONTACT: Stephanie Marrus, Vertex director of corporate communication, 617-576-3111, or Robert Gottlieb, Feinstein Partners, 617-577-8110, for Vertex/
 (VRTX) CO: Vertex Pharmaceuticals Incorporated ST: Massachusetts IN: MTC SU: PER


CN -- NE007 -- 9606 08/13/92 11:45 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 13, 1992
Words:302
Previous Article:Rx MEDICAL SERVICES CORP. REPORTS RECORD REVENUE AND EARNINGS IN SECOND QUARTER OF 1992
Next Article:SAN FRANCISCO PRICES ROSE 0.2 PERCENT IN JULY
Topics:


Related Articles
VICKI SATO TO HEAD RESEARCH AT VERTEX PHARMACEUTICALS
ROGER W. BRIMBLECOMBE, Ph.D., JOINS VERTEX BOARD OF DIRECTORS
ROBERT SCHOOLEY, M.D., JOINS VERTEX SCIENTIFIC ADVISORY BOARD
DONALD R. CONKLIN AND BARRY M. BLOOM NAMED TO VERTEX BOARD OF DIRECTORS
CREATIVE BIOMOLECULES, INC. APPOINTS VICE PRESIDENT, CORPORATE DEVELOPMENT
LYNNE H. BRUM JOINS VERTEX PHARMACEUTICALS AS DIRECTOR OF CORPORATE COMMUNICATIONS
VERTEX PHARMACEUTICALS APPOINTS BART HENDERSON DIRECTOR OF MARKETING
Steven Schmidt Joins Vertex Pharmaceuticals as Director of Information Systems
Vertex Pharmaceuticals Appoints Andrew S. Marks as Patent Counsel
James P. Feeney Joins Vertex Pharmaceuticals as Senior Director of Business Development

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters